268 related articles for article (PubMed ID: 29985478)
1. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol.
Wang L; Smith J; Breton C; Clark P; Zhang J; Ying L; Che Y; Lape J; Bell P; Calcedo R; Buza EL; Saveliev A; Bartsevich VV; He Z; White J; Li M; Jantz D; Wilson JM
Nat Biotechnol; 2018 Sep; 36(8):717-725. PubMed ID: 29985478
[TBL] [Abstract][Full Text] [Related]
2. Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9.
Wang L; Breton C; Warzecha CC; Bell P; Yan H; He Z; White J; Zhu Y; Li M; Buza EL; Jantz D; Wilson JM
Mol Ther; 2021 Jun; 29(6):2019-2029. PubMed ID: 33609733
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
Chadwick AC; Wang X; Musunuru K
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
[TBL] [Abstract][Full Text] [Related]
4. Increasing the Specificity of AAV-Based Gene Editing through Self-Targeting and Short-Promoter Strategies.
Breton C; Furmanak T; Avitto AN; Smith MK; Latshaw C; Yan H; Greig JA; Wilson JM
Mol Ther; 2021 Mar; 29(3):1047-1056. PubMed ID: 33359790
[TBL] [Abstract][Full Text] [Related]
5. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
[TBL] [Abstract][Full Text] [Related]
6. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
[TBL] [Abstract][Full Text] [Related]
7. Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys.
Wang Y; Ma M; Wang JA; Daugherty A; Lu HS
Curr Opin Lipidol; 2019 Apr; 30(2):154-155. PubMed ID: 30844857
[No Abstract] [Full Text] [Related]
8. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
[TBL] [Abstract][Full Text] [Related]
9. Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells.
Yang J; Wang Y; Zhou T; Wong LY; Tian XY; Hong X; Lai WH; Au KW; Wei R; Liu Y; Cheng LH; Liang G; Huang Z; Fan W; Zhao P; Wang X; Ibañez DP; Luo Z; Li Y; Zhong X; Chen S; Wang D; Li L; Lai L; Qin B; Bao X; Hutchins AP; Siu CW; Huang Y; Esteban MA; Tse HF
Stem Cell Reports; 2017 Mar; 8(3):605-618. PubMed ID: 28262545
[TBL] [Abstract][Full Text] [Related]
10. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
Dong B; Singh AB; Shende VR; Liu J
Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
[TBL] [Abstract][Full Text] [Related]
11. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
14. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
15. Targeting PCSK9 for the treatment of hypercholesterolemia.
Hedrick JA
Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
[TBL] [Abstract][Full Text] [Related]
16. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
17. Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels.
Jiang C; Nischal H; Sun H; Li L; Cao Y; Wei P; Chang JY; Teng BB
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29495280
[TBL] [Abstract][Full Text] [Related]
18. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
19. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.
Musunuru K; Chadwick AC; Mizoguchi T; Garcia SP; DeNizio JE; Reiss CW; Wang K; Iyer S; Dutta C; Clendaniel V; Amaonye M; Beach A; Berth K; Biswas S; Braun MC; Chen HM; Colace TV; Ganey JD; Gangopadhyay SA; Garrity R; Kasiewicz LN; Lavoie J; Madsen JA; Matsumoto Y; Mazzola AM; Nasrullah YS; Nneji J; Ren H; Sanjeev A; Shay M; Stahley MR; Fan SHY; Tam YK; Gaudelli NM; Ciaramella G; Stolz LE; Malyala P; Cheng CJ; Rajeev KG; Rohde E; Bellinger AM; Kathiresan S
Nature; 2021 May; 593(7859):429-434. PubMed ID: 34012082
[TBL] [Abstract][Full Text] [Related]
20. Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets.
Conway A; Mendel M; Kim K; McGovern K; Boyko A; Zhang L; Miller JC; DeKelver RC; Paschon DE; Mui BL; Lin PJC; Tam YK; Barbosa C; Redelmeier T; Holmes MC; Lee G
Mol Ther; 2019 Apr; 27(4):866-877. PubMed ID: 30902585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
